R. Katherine Hyde

Nebraska Medical Center — United States

Medicine · Health Sciences

20h-index1.2kcitations77works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(43), Protein Degradation and Inhibitors(17), Histone Deacetylase Inhibitors Research(12), Chronic Myeloid Leukemia Treatments(10), Acute Lymphoblastic Leukemia research(6)

Publications77 total

The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival
Leukemia·2025Open Access
Tissue specific requirement for the inv(16) oncogene CBFB::MYH11 implies unique leukemia survival mechanisms in the bone marrow microenvironment
Blood·2025Open Access
Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma–GATA3 molecular subgroup
Science Advances·2025Open Access
PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
2025Open Access
The Splicing Factor PTBP1 interacts with RUNX1 and is Required for Leukemia Cell Survival
2025Open Access
Leukemic Cells Infiltrate the Ovaries Without Damaging Ovarian Reserve in an Acute Myeloid Leukemia Mouse Model
Endocrinology·2025Open Access
Small molecule targeting of FBXO21 mediated p85α ubiquitylation in acute myeloid leukemia
2024
PTBP1, an RNA Binding Protein and Splicing Regulator, Binds RUNX1 and Co-Localizes at Target Gene Promoters in Leukemia
Blood·2024Open Access
Tissue Specific Requirement for the Inv(16) Oncogene <i>CBFB::MYH11</i> in Acute Myeloid Leukemia
2024Open Access
Anti-CLL1 liposome loaded with miR-497-5p and venetoclax as a novel therapeutic strategy in acute myeloid leukemia
Molecular Therapy·2024· 9 citedOpen Access
FBXO21 mediated degradation of p85α regulates proliferation and survival of acute myeloid leukemia
Leukemia·2023· 10 citedOpen Access
Data from HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia
2023Open Access
Data from HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia
2023Open Access
Supplementary Data, Figures and Table from HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia
2023Open Access
Supplementary Data, Figures and Table from HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia
2023Open Access
3218 – INVESTIGATING THE ROLE OF UBIQUITIN E3 LIGASE FBXO21 IN CYTOKINE MEDIATED SIGNALING WITHIN ACUTE MYELOID LEUKEMIA
Experimental Hematology·2023
Polymeric CXCR4 Inhibitors Exhibit Novel Anti-Leukemic Effects
Blood·2022
<i>CBFB-MYH11</i> Is Required for the Maintenance of Inv(16) AML
Blood·2022· 1 cited
Synthetic Immunotherapy: Programming Immune Cells with Novel and Sophisticated Logic Capabilities
Transplantation and Cellular Therapy·2022· 7 cited
Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia
Journal of Geriatric Oncology·2022· 23 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Lemlem Alemu(10), Ling Zhao(9), Paul Liu(9), Yiqian Wang(8), Samantha Swenson(7), Shannon M. Buckley(7), Lisa Richter(7), Michelle Becker(7), John K. Field(5), Michael P.A. Davies(5), Yasuhiko Kamikubo(5), Karli J. Wittorf(5), Catalina Amador(5), Peiqing Liu(4), Lisa Garrett(4), Calvin Lam(4), Anne E. Griep(3), R. Willow Hynes-Smith(3), Mika Caplan(3), Vijaya Raj Bhatt(3)